WO2004084871A1 - Intravenous nanoparticles for targenting drug delivery and sustained drug release - Google Patents

Intravenous nanoparticles for targenting drug delivery and sustained drug release Download PDF

Info

Publication number
WO2004084871A1
WO2004084871A1 PCT/JP2004/003246 JP2004003246W WO2004084871A1 WO 2004084871 A1 WO2004084871 A1 WO 2004084871A1 JP 2004003246 W JP2004003246 W JP 2004003246W WO 2004084871 A1 WO2004084871 A1 WO 2004084871A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
nanoparticles
water
soluble
molecular weight
Prior art date
Application number
PCT/JP2004/003246
Other languages
French (fr)
Inventor
Tsutomu Ishihara
Yutaka Mizushima
Original Assignee
Ltt Bio-Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltt Bio-Pharma Co., Ltd. filed Critical Ltt Bio-Pharma Co., Ltd.
Priority to AU2004224530A priority Critical patent/AU2004224530A1/en
Priority to CA002518223A priority patent/CA2518223A1/en
Priority to JP2006507664A priority patent/JP2006521367A/en
Priority to US10/550,990 priority patent/US20060233883A1/en
Priority to EP04719616A priority patent/EP1594482A1/en
Publication of WO2004084871A1 publication Critical patent/WO2004084871A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to intravenous nanoparticles encapsulating low-molecular weight, water-soluble and non-peptide drugs that are intended for the purposes of targeting drug delivery and sustained drug release.
  • the invention also relates to a production method of such nanoparticles .
  • the present invention relates to intravenous nanoparticles which can deliver low-molecular weight, water-soluble and non-peptide drugs to target lesion site where the particles gradually release the drugs over a prolonged period of time, and a production method thereof.
  • intravenous nanoparticles mean nanoparticles for intravenous administration containing drugs.
  • US patent No. 4,652,441 describes PLGA microcapsules containing physiologically active polypeptides and a production method thereof.
  • Japanese National Publication No. Hei 10- 511957 describes PLGA nanoparticles for intravascular administration containing various therapeutic agents.
  • Japanese Patent Laid- Open Publication No. Hei 8-217691 discloses a sustained-release formulation comprising PLGA microcapsules encapsulating physiologically active, water-soluble peptide compounds, which were prepared -in the form of water-insoluble or hardly water-soluble polyvalent metal salts .
  • the present inventors also have filed patent applications (e.g., Japanese Patent Application No. 2002-159190) concerning formulations comprising poly(lactic-co-glycolic acid) (PLGA) or poly (lactic acid) (PLA) nanoparticles.
  • PLGA poly(lactic-co-glycolic acid)
  • PLA poly (lactic acid)
  • the nanoparticles suggested by the present inventors could only offer a low encapsulation efficiency of the low-molecular weight, water-soluble drugs . Attempts were therefore made to increase the hydrophobicity and thereby the encapsulation rate of the drug through processes including esterification. However, such attempts resulted in a decrease in the length of time over which the nanoparticles can release the encapsulated drug, though the encapsulation rate was improved to some extent. In other words, the desired sustained drug- releasing property of the nanoparticles was compromised in these approaches.
  • the present inventors drew attention to the fact that low-molecular weight, water-soluble and non-peptide drugs interact with certain metal ions .
  • the present inventors have examined the possibility of allowing such low-molecular weight, water-soluble and non-peptide drugs to bind to metal ion to impart a hydrophobicity to the drugs, thereby facilitating encapsulation of the drugs into PLGA or PLA nanoparticles.
  • the present inventors have discovered that such drugs, when bound to a metal ion, become hydrophobic and thus can be readily encapsulated in PLGA or PLA nanoparticles .
  • one aspect of the present invention concerns intravenous nanoparticles designed for targeting drug delivery and sustained drug release.
  • the nanoparticles are characterized in that a low-molecular weight, water-soluble and non-peptide drug is made hydrophobic by a metal ion and is encapsulated in nanoparticles formed of poly (lactic-co-glycolic acid) (PLGA) or poly (lactic acid) (PLA) , and a surfactant is applied to the surface of the PLGA or PLA nanoparticles .
  • PLGA poly (lactic-co-glycolic acid)
  • PLA poly (lactic acid)
  • the PLGA or PLA nanoparticles has a diameter of 50 to 300 rim.
  • the low-molecular weight, water- soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a molecular weight of 1000 or lower.
  • the metal ion to be bound to the low-molecular weight, water-soluble and non-peptide drug is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
  • the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a phosphate group or a carboxyl group in its molecule.
  • the low-molecular weight, water-soluble and non-peptide drug is a steroidal anti- inflammatory agent, a non-steroidal anti-inflammatory agent, a prostanoid, an antimicrobial agent, or an anticancer agent.
  • the surfactant to coat the surface of the PLGA or PLA nanoparticles encapsulating the low-molecular weight, water-soluble and non-peptide drug is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, a lecithin, or a polyvinylalcohol .
  • Another aspect of the present invention concerns a method for producing intravenous nanoparticles for targeting drug delivery and sustained drug release.
  • the method comprises the steps of hydrophobicizing a low-molecular weight, water-soluble and non- peptide drug by the use of metal ion; dissolving or suspending, along with PLGA or PLA, the low-molecular weight, non-peptide drug in a water-miscible organic solvent; and adding the resulting solution or the suspension to an aqueous solution of a surfactant to apply the surfactant to the surface of the PLGA or PLA nanoparticles.
  • the resulting PLGA or PLA particles have a diameter 50 to 300nm.
  • the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a molecular weight of 1000 or lower.
  • the metal ion to be bound to the low-molecular weight, water-soluble and non-peptide drug is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
  • the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a phosphate group or a carboxyl group in its molecule.
  • the low-molecular weight, water-soluble and non-peptide drug is a steroidal anti-inflammatory agent, a non-steroidal anti- inflammatory agent, a prostanoid, an antimicrobial agent, or an anticancer agent.
  • the surfactant to coat the surface of the PLGA or PLA nanoparticles encapsulating the low-molecular weight, water-soluble and non-peptide drug is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, a lecithin, or a polyvinylalcohol .
  • Another aspect of the present invention concerns a therapeutic preparation containing as an active ingredient the above-described nanoparticles.
  • the therapeutic preparation is an anti- inflammatory/anti-rheumatoid agent containing as an active ingredient the nanoparticles encapsulating a water-soluble steroid.
  • the present invention comprises biodegradable PLGA or PLA nanoparticles; a low-molecular weight, water-soluble and non-peptide drug bound to a metal ion and encapsulated in the nanoparticles; and a surfactant applied to the surfaces of the nanoparticles.
  • the intravenous nanoparticles of the present invention designed for targeting drug delivery and sustained drug release comprise a low-molecular weight, water-soluble and non- peptide drug that has been hydrophobicized with a metal ion and has been encapsulated in PLGA or PLA nanoparticles with a surfactant subsequently applied to their surfaces.
  • the nanoparticles of the present invention are most effectively uptaken by the target lesion site when they have a diameter of 50 to 300nm.
  • nanoparticles having a diameter less than 50nm tend to be uptaken by- regions other than the intended lesion sites and are therefore undesirable, as are the nanoparticles having a diameter larger than 300nm, which tend to be uptaken by endothelial cells.
  • the low-molecular weight, water-soluble and non-peptide drug is bound to a metal ion so that the low-molecular weight drug will become hydrophobic and is thus effectively encapsulated in the nanoparticles.
  • metal ions suitable for this purpose are zinc ion, iron ion, copper ion, nickel ion, beryllium ion, manganese ion, and cobalt ion. Of these, zinc ion and iron ion are particularly preferred.
  • the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles in accordance with the present invention preferably includes a phosphate group or a carboxyl group in its molecule so that the drug can readily bind to the metal ion to become hydrophobic.
  • the low-molecular weight, water-soluble and non- peptide drug has a molecular weight of 1000 or less.
  • water-soluble and non-peptide drug in the present invention, particularly preferred are water-soluble steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, prostanoids, antimicrobial agents, and anticancer agents.
  • steroidal anti-inflammatory agents include betamethasone phosphate, dexa ethasone phosphate, prednisolone phosphate, hydrocortisone phosphate, prednisolone succinate, and hydrocortisone succinate.
  • non-steroidal anti-inflammatory agents examples include loxoprofen sodium, and diclofenac sodium.
  • prostanoids examples include Prostaglandin Ei (PGEx)
  • antimicrobial agents include vancomycin, chloramphenicol succinate, latamoxef, cefpirome, clindamycin phosphate, and carumonam.
  • anticancer agents include, but are not limited to, vincristin, and vinblastine.
  • the intravenous nanoparticles are produced in the following manner: The low-molecular weight, water-soluble and non-peptide drug is first bound to the metal ion to make the agent hydrophobic.
  • the drug is then dissolved or suspended, along with PLGA or PLA, in a water- miscible organic solvent.
  • the resulting solution or suspension is added to an aqueous solution of a surfactant and the mixture is stirred to obtain the desired nanoparticles.
  • water-miscible organic solvents for use in the present invention include, but are not limited to, acetone, acetonitrile, ethanol, methanol, propanol, dimethylformamide, dimethylsulfoxide, dioxane, and mixtures thereof.
  • surfactants examples include polyoxyethylene polyoxypropylene glycols, polysorbates, polyoxyethylene octylphenyl ethers, lecithin, and polyvinylalcohol.
  • the nanoparticles of the present invention so produced are purified by centrifugation, gel filtration, fiber dialysis, or ultrafiltration and are subsequently freeze-dried for storage to ensure the stability of PLGA or PLA as ingredient.
  • a stabilizing agent and an isotonizing agent are preferably added to the nanoparticles suspension so that the freeze-dried preparation can be resuspended for administration.
  • Preferred examples of the stabilizing agent and isotonizing agent include sucrose and trehalose, which are preferably added in an amount (by weight) 5 times or greater than the amount of the nanoparticles .
  • the nanoparticles prepared in the above-described manner are intravenously administered to target various inflammatory sites, vascular lesions, infected sites, and malignant tumor tissues where the particles effectively accumulate and sustainedly release the encapsulated low-molecular weight, water-soluble and non-peptide drug over time to provide the desired biological activities for a prolonged period of time.
  • the metal ion acts to prevent the encapsulated low-molecular weight, water- soluble and non-peptide drug from bursting release out of the nanoparticles at an early stage after administration, thereby allowing the sustained release of the drug for a prolonged period of time.
  • the nanoparticles in order for the nanoparticles to be usable as a medical formulation, it is important to control, depending on the intended purposes, the surface properties and the particle size of the nanoparticles, as well as the encapsulation rate and the release profile of the • low-molecular weight, water-soluble and non-peptide drug.
  • the surface properties of the nanoparticles can be controlled by using different types of surfactants.
  • Adjusting the particle size of the nanoparticles is important also because the distribution of the nanoparticles within living body is strongly influenced by the particle size.
  • the size of the nanoparticles is adjusted by taking into account how well the particles accumulate to different lesion sites (e.g., inflammatory sites, vascular lesion sites, infected sites, and malignant tumor tissues) .
  • the particle size can be adjusted by controlling the conditions during the preparation of the nanoparticles, including the rate at which the aqueous phase is stirred, the amount of the organic solvent used, and the rate at which the organic solvent is added to aqueous phase.
  • the efficiency of encapsulation of the low-molecular weight, water-soluble and non-peptide drug into the PLGA or PLA nanoparticles largely depends on the physical properties of the low- molecular weight drug.
  • hydrophilic (water-soluble) drugs tend to be incorporated into the PLGA or PLA nanoparticles less efficiently than hydrophobic drugs.
  • the low- molecular weight, water-soluble and non-peptide drug for use in the present invention needs to be bound to a metal ion to impart a hydrophobicity to the agent. Specifically, this is done by allowing the low-molecular weight, water-soluble and non-peptide drug to bind to a metal ion in such a manner that the drug forms water-insoluble precipitates .
  • such functional groups as phosphate and carboxyl, which are capable of binding to the metal ion are preferably introduced into the molecules of the low-molecular weight, water-soluble and non-peptide drug. It is also required that any functional groups present in the drug molecules that do not participate in, or interrupt, the formation of the precipitation with the metal ion must be protected with proper protective groups. Furthermore, the type and amount of the organic solvent used and the rate at which the organic solvent is poured also affect the particle size of the nanoparticles and therefore need to be optimized.
  • PLGA or PLA with different molecular weights may be used to adjust the rate at which the encapsulated low-molecular weight, water-soluble and non-peptide drug is released from the nanoparticles .
  • the present invention has achieved a high encapsulation rate of the low-molecular weight, water-soluble and non-peptide drug into the PLGA or PLA nanoparticles by the use of metal ions to impart a hydrophobicity to the drug.
  • the present invention allows the simple, industrial-scale production of the intravenous nanoparticles designed for the purpose of targeting drug delivery to target lesion sites where the particles can gradually release the drug over a prolonged period of time.
  • Example 1 Formation of water-insoluble precipitates of low- molecular weight, water-soluble and non-peptide drug with metal ion
  • Table 1 Compounds shown in Table 1 below were used to as the low- molecular weight, water-soluble and non-peptide drug having phosphate groups. Each compound was dissolved in a 0.2M Tris-HCl • buffer solution (pH7.8) to a concentration of 20mM. The solution was then added to equal volume of lOOmM aqueous solutions of different metal ions. The turbidity of each of the resulting mixtures was observed.
  • the resulting mixture was evaluated as follows: -: the compound was dissolved; +: the mixture was slightly turbid;
  • Example 2 Preparation of PLGA/PLA nanoparticles encapsulating steroids
  • the residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles.
  • the resulting nanoparticles were added to a 2N aqueous solution of NaOH to decompose PLGA/PLA, and the steroid content in the nanoparticles was determined by HPLC.
  • the amount of water-insoluble steroid was determined for the nanoparticles prepared by different method without metal ions .
  • precipitates formed by mixing 5mg betamethasone phosphate with zinc were dissolved in varying volume of acetone and then encapsulation efficiency of betamethasone phosphate incorporated in the nanoparticles was determined in the same manner as described above.
  • BDP betamethasone dipropionate
  • BP betamethasone phosphate
  • DP dexamethasone phosphate
  • HP hydrocortisone phosphate
  • the use of the precipitates of the steroid phosphates that were generated through the addition of zinc or ferrous ion significantly increased the encapsulation rate of the respective steroids into PLGA nanoparticles, as opposed to the cases of the steroid phosphates provided in the form of sodium salts, each of which showed substantially no incorporation into the nanoparticles.
  • Table 3 shows the encapsulation rates of betamethasone phosphate into PLGA nanoparticles obtained by varying the amount of the solvent, acetone, while maintaining the amounts of PLGA and betamethasone phosphate.
  • the nanoparticles formed aggregates in 500 ⁇ l or less of acetone.
  • the particles on the other hand remained stably dispersed in 700 ⁇ l acetone while showing a high encapsulation rate of betamethasone phosphate into the nanoparticles.
  • the nanoparticles were stably dispersed in 700 ⁇ l or more acetone, the encapsulation rates gradually decreased as the amount of acetone was increased.
  • Example 3 Steroid release profile from PLGA/PLA nanoparticles
  • betamethasone phosphate was dissolved in lOO ⁇ l water and the solution was added to 500 ⁇ l of a 0.5M aqueous solution of zinc acetate. The mixture was then centrifuged at 12,000rpm for 5min and the supernatant was discarded to obtain a zinc-steroid precipitate. To the precipitate, 500 ⁇ l of acetone dissolved 20mg of PLGAs or PLAs with different molecular weights was added.
  • the solution was allowed to stand for 2 hours at room temperature and was subsequently added, at a rate of lml/min with a 27G syringe, to a 0.5% suspension of either Pluronic F68 (a nonionic high-molecular weight surfactant) or lecithin that had been stirred at 400rpm.
  • Pluronic F68 a nonionic high-molecular weight surfactant
  • lecithin lecithin
  • FBS fetal bovine serum
  • PBS fetal bovine serum
  • a 0.5M aqueous solution of EDTA pH8
  • the suspension was then centrifuged at 20,000G for 30min and the supernatant was discarded.
  • the residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles .
  • the resulting nanoparticles were added to a 2N aqueous solution of NaOH to hydrolyze PLGA/PLA, and the steroid content in the nanoparticles was determined by HPLC.
  • Patent Application No. 2002-159190 *2 Nanoparticles prepared according to the method of the present invention
  • the nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, and prepared according to the method previously proposed by the present inventors (Japanese Patent Application No. 2002-159190) released a significant amounts of betamethasone at an early stage with approximately 90% or more of betamethasone having been released after 6 days.
  • the nanoparticles prepared according to the method of the present invention in which the steroid's initial bursting release is significantly reduced, released the steroid in a more gradual manner and were able to release it over an extended period of time.
  • nanoparticles made of PLGA or PLA with small molecular weights tend to release the steroid at an earlier stage and that the nanoparticles made of PLGA tend to release the steroid earlier than those made of PLA.
  • Macrophages were collected from the abdominal cavities of mice that had been stimulated by intraperitoneal administration of 1.5ml of 10% proteose peptone.
  • the cells were inoculated at 6 x 10 5 cells/12 wells and were cultured overnight in Macrophage-SFM medium (Gibco) . Subsequently, the culture medium was replaced, and the PLGA or PLA nanoparticles prepared according to the procedures described in Example 3 were added. The cells were incubated at 37 °C for another 2 hours . Subsequently, the cells were washed 8 times with PBS and the medium, and the amount of betamethasone in the medium was determined at pre-determined intervals by ELISA method.
  • nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, were prepared according to a method previously proposed by the present inventors (Japanese Patent Application No. 2002-159190) and were also added to the cells.
  • Nanoparticles prepared using PLGA (MW 8,000)
  • the acetone solutions prepared according to the procedures described in Example 3 were added dropwise to aqueous solutions of different surfactants to obtain nanoparticles .
  • the resulting nanoparticles were concentrated, washed, purified, and were then freeze-dried in sucrose solutions of varying concentrations .
  • the freeze-dried nanoparticles were resuspended in water and particle sizes of the particles were measured using a light-scattering photometer. All of the nanoparticles prepared by using aqueous solutions of different surfactants, namely, lecithin, polyoxyethylene polyoxypropylene glycols, and polysorbates, had substantially the same particle size.
  • the nanoparticles prepared with a polyvinylalcohol solution were larger in size than those prepared with other surfactants and had a low encapsulation rate of betamethasone phosphate. It was also shown that the re- dispersibility of the freeze-dried nanoparticles by adding sucrose in an amount (by weight) more than 5 times the amount of the nanoparticles prior to freeze-drying the nanoparticles .
  • Example 6 Accumulation of nanoparticles in inflammatory sites
  • the intensity of fluorescence observed in tissue sections was significantly higher in the group given the 200nm nanoparticles than in the control group given physiological saline alone, indicating significant accumulation of the nanoparticles in the inflammatory sites.
  • Betamethasone phosphate-encapsulating nanoparticles were prepared using PLA (MW 14000) . Nanoparticles were given in an amount corresponding to lOO ⁇ g Betamethasone phosphate.
  • Inflammation rate (%) (measured leg volume - leg volume of normal rat un-injected adjuvant) / (leg volume before steroid administration - leg volume of normal rat un-injected adjuvant) x 100
  • Example 8 Preparation of PLGA/PLA nanoparticles encapsulating PGEj lmg of PGEi was dissolved in 20 ⁇ l ethanol and the solution was added to an 80 ⁇ l 0.5M aqueous solution of ferrous (or ferric) chloride. The mixture was then centrifuged at 12,000rpm for 5min and the supernatant was removed to obtain an iron-PGEi precipitate. To this precipitate, PLGA (WAKO PURE CHEMICAL INDUSTRIES, LTD.) or PLA (WAKO PURE CHEMICAL INDUSTRIES, LTD.) in acetone was added. An aqueous solution of zinc acetate was further added and the solution was allowed to stand for 2 hours at room temperature.
  • PLGA WAKO PURE CHEMICAL INDUSTRIES, LTD.
  • PLA WAKO PURE CHEMICAL INDUSTRIES, LTD.
  • the solution (or suspension) was subsequently added, at a rate of lml/min, to a 0.5% suspension of either Pluronic F68 (a nonionic high-molecular weight surfactant) or lecithin that had been pre-stirred at 400rpm.
  • Pluronic F68 a nonionic high-molecular weight surfactant
  • lecithin that had been pre-stirred at 400rpm.
  • the resulting nanoparticles were stirred for 1 to 2 hours at room temperature and a 0.5M aqueous solution of EDTA (pH8) was added (0.4 by volume).
  • the suspension was then centrifuged at 20,OOOG for 20min and the supernatant was discarded.
  • the residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles.
  • the resulting nanoparticles were dissolved in acetonitrile, followed by dilution with PBS. The amount of PGEi was then determined by EL
  • Nanoparticles prepared using PLGA (MW 8,000)
  • the encapsulation rate of PGE X into the PLGA nanoparticles was approximately 0.1 to 1% by weight .
  • PGEi was continuously released from the nanoparticles for 8 days although the release profile was not as good as that for betamethasone phosphate, a steroidal anti- inflammatory agent.
  • the present invention provides intravenous PLGA or PLA nanoparticles that can encapsulate sufficient amounts of low- molecular weight, water-soluble and non-peptide drugs are less likely to burst at an early stage of administration, and are capable of releasing the drug for a prolonged period of time.
  • the intravenous nanoparticles of the present invention can be used to target various inflammatory sites, vascular lesion sites, infectious sites, and malignant tumor tissues and effectively accumulate in such sites or tissues where the encapsulated low- molecular weight, water-soluble and non-peptide drugs are released over time to exhibit their biological activities for a prolonged period of time.
  • the potential medical impact that the nanoparticles of the present invention can bring about is thus significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are poly(lactic-co-glycolic acid) (PLGA) and poly(lactic acid) (PLA) nanoparticles that encapsulate a low­ molecular weight and water-soluble drug and can deliver the drug to target legion sites where the particles gradually release the drug over a prolonged period of time. The nanoparticles are prepared by allowing the low-molecular, water-soluble and non-peptide drug to interact with a metal ion so as to make the drug hydrophobic, encapsulating the hydrophobicized drug into PLGA or PLA nanoparticles, and allowing a surfactant to be adsorbed onto the surface of the particles.

Description

DESCRIPTION
INTRAVENOUS NANOPARTICLES FOR TARGETING DRUG DELIVERY AND SUSTAINED DRUG RELEASE
TECHNICAL FIELD
The present invention relates to intravenous nanoparticles encapsulating low-molecular weight, water-soluble and non-peptide drugs that are intended for the purposes of targeting drug delivery and sustained drug release. The invention also relates to a production method of such nanoparticles . Specifically, the present invention relates to intravenous nanoparticles which can deliver low-molecular weight, water-soluble and non-peptide drugs to target lesion site where the particles gradually release the drugs over a prolonged period of time, and a production method thereof. Hereon, intravenous nanoparticles mean nanoparticles for intravenous administration containing drugs.
BACKGROUND ART Many researchers have developed and proposed poly (lactic-co- glycolic acid) (PLGA) or poly (lactic acid) (PLA) microparticles and nanoparticles that encapsulate low-molecular weight, water-soluble drugs .
For example, US patent No. 4,652,441 describes PLGA microcapsules containing physiologically active polypeptides and a production method thereof. Japanese National Publication No. Hei 10- 511957 describes PLGA nanoparticles for intravascular administration containing various therapeutic agents. Also, Japanese Patent Laid- Open Publication No. Hei 8-217691 discloses a sustained-release formulation comprising PLGA microcapsules encapsulating physiologically active, water-soluble peptide compounds, which were prepared -in the form of water-insoluble or hardly water-soluble polyvalent metal salts . However, none of these patent publications mention or suggest the concept of hydrophobicizing a low-molecular weight, water- soluble and non-peptide drug with the use of metal ions prior to the encapsulation of the drug into nanoparticles so as to make intravenous nanoparticles suitable for the targeting delivery and sustained release of drugs.
The present inventors also have filed patent applications (e.g., Japanese Patent Application No. 2002-159190) concerning formulations comprising poly(lactic-co-glycolic acid) (PLGA) or poly (lactic acid) (PLA) nanoparticles. The nanoparticles suggested by the present inventors, however, could only offer a low encapsulation efficiency of the low-molecular weight, water-soluble drugs . Attempts were therefore made to increase the hydrophobicity and thereby the encapsulation rate of the drug through processes including esterification. However, such attempts resulted in a decrease in the length of time over which the nanoparticles can release the encapsulated drug, though the encapsulation rate was improved to some extent. In other words, the desired sustained drug- releasing property of the nanoparticles was compromised in these approaches.
Accordingly, it is an objective of the present invention to provide intravenous nanoparticles encapsulating a low-molecular weight, water-soluble and non-peptide drug that are capable of targeting a specific lesion site and are less likely to burst at an early stage of administration so that they can gradually release the drug at the lesion site over a prolonged period of time.
It is another objective of the present invention to provide a simple method for preparing such intravenous nanoparticles that enables large-scale production of the product.
In an effort to attain the above-described goals, the present inventors drew attention to the fact that low-molecular weight, water-soluble and non-peptide drugs interact with certain metal ions . Specifically, the present inventors have examined the possibility of allowing such low-molecular weight, water-soluble and non-peptide drugs to bind to metal ion to impart a hydrophobicity to the drugs, thereby facilitating encapsulation of the drugs into PLGA or PLA nanoparticles. As a result, the present inventors have discovered that such drugs, when bound to a metal ion, become hydrophobic and thus can be readily encapsulated in PLGA or PLA nanoparticles . In fact, it has proven that the encapsulation efficiency of the incorporation of the hydrophobicized drugs into the nanoparticles was extremely high. The present inventors have also discovered that the nanoparticles so produced have an ability to gradually release the drugs over time and tend to accumulate specific lesion sites in living body. This implied the possibility that such nanoparticles can be suitably used in designing a formulation for effective targeted drug delivery and sustained drug release. The discoveries ultimately led the present inventors to devise the present invention.
DISCLOSURE OF THE INVENTION
Accordingly, one aspect of the present invention concerns intravenous nanoparticles designed for targeting drug delivery and sustained drug release. The nanoparticles are characterized in that a low-molecular weight, water-soluble and non-peptide drug is made hydrophobic by a metal ion and is encapsulated in nanoparticles formed of poly (lactic-co-glycolic acid) (PLGA) or poly (lactic acid) (PLA) , and a surfactant is applied to the surface of the PLGA or PLA nanoparticles .
In one specific embodiment of the intravenous nanoparticles according to the present invention, the PLGA or PLA nanoparticles has a diameter of 50 to 300 rim. In one specific embodiment of the intravenous nanoparticles according to the present invention, the low-molecular weight, water- soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a molecular weight of 1000 or lower. In another specific embodiment of the intravenous nanoparticles according to the present invention, the metal ion to be bound to the low-molecular weight, water-soluble and non-peptide drug is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
In a further specific embodiment of the intravenous nanoparticles according to the present invention, the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a phosphate group or a carboxyl group in its molecule.
In a still more specific embodiment of the intravenous nanoparticles according to the present invention, the low-molecular weight, water-soluble and non-peptide drug is a steroidal anti- inflammatory agent, a non-steroidal anti-inflammatory agent, a prostanoid, an antimicrobial agent, or an anticancer agent.
In a still more specific embodiment of the intravenous nanoparticles, the surfactant to coat the surface of the PLGA or PLA nanoparticles encapsulating the low-molecular weight, water-soluble and non-peptide drug is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, a lecithin, or a polyvinylalcohol .
Another aspect of the present invention concerns a method for producing intravenous nanoparticles for targeting drug delivery and sustained drug release. Specifically, the method comprises the steps of hydrophobicizing a low-molecular weight, water-soluble and non- peptide drug by the use of metal ion; dissolving or suspending, along with PLGA or PLA, the low-molecular weight, non-peptide drug in a water-miscible organic solvent; and adding the resulting solution or the suspension to an aqueous solution of a surfactant to apply the surfactant to the surface of the PLGA or PLA nanoparticles. In one specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the resulting PLGA or PLA particles have a diameter 50 to 300nm. In another specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a molecular weight of 1000 or lower.
In a further specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the metal ion to be bound to the low-molecular weight, water-soluble and non-peptide drug is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
In a still more specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles has a phosphate group or a carboxyl group in its molecule.
In a still more specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the low-molecular weight, water-soluble and non-peptide drug is a steroidal anti-inflammatory agent, a non-steroidal anti- inflammatory agent, a prostanoid, an antimicrobial agent, or an anticancer agent.
In a still more specific embodiment of the method for producing intravenous nanoparticles according to the present invention, the surfactant to coat the surface of the PLGA or PLA nanoparticles encapsulating the low-molecular weight, water-soluble and non-peptide drug is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, a lecithin, or a polyvinylalcohol .
Another aspect of the present invention concerns a therapeutic preparation containing as an active ingredient the above-described nanoparticles. Specifically, the therapeutic preparation is an anti- inflammatory/anti-rheumatoid agent containing as an active ingredient the nanoparticles encapsulating a water-soluble steroid. BEST MODE FOR CARRYING OUT THE INVENTION
As described above, the present invention comprises biodegradable PLGA or PLA nanoparticles; a low-molecular weight, water-soluble and non-peptide drug bound to a metal ion and encapsulated in the nanoparticles; and a surfactant applied to the surfaces of the nanoparticles.
Specifically, the intravenous nanoparticles of the present invention designed for targeting drug delivery and sustained drug release comprise a low-molecular weight, water-soluble and non- peptide drug that has been hydrophobicized with a metal ion and has been encapsulated in PLGA or PLA nanoparticles with a surfactant subsequently applied to their surfaces. In this regard, it has been found that the nanoparticles of the present invention are most effectively uptaken by the target lesion site when they have a diameter of 50 to 300nm. The nanoparticles having a diameter less than 50nm tend to be uptaken by- regions other than the intended lesion sites and are therefore undesirable, as are the nanoparticles having a diameter larger than 300nm, which tend to be uptaken by endothelial cells.
One characteristic feature of the present invention is that the low-molecular weight, water-soluble and non-peptide drug is bound to a metal ion so that the low-molecular weight drug will become hydrophobic and is thus effectively encapsulated in the nanoparticles. Among the metal ions suitable for this purpose are zinc ion, iron ion, copper ion, nickel ion, beryllium ion, manganese ion, and cobalt ion. Of these, zinc ion and iron ion are particularly preferred. For this reason, the low-molecular weight, water-soluble and non-peptide drug to be encapsulated in the PLGA or PLA nanoparticles in accordance with the present invention preferably includes a phosphate group or a carboxyl group in its molecule so that the drug can readily bind to the metal ion to become hydrophobic.
Preferably, the low-molecular weight, water-soluble and non- peptide drug has a molecular weight of 1000 or less.
While various drugs can be used as the low-molecular weight, water-soluble and non-peptide drug in the present invention, particularly preferred are water-soluble steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, prostanoids, antimicrobial agents, and anticancer agents.
Specific examples of steroidal anti-inflammatory agents include betamethasone phosphate, dexa ethasone phosphate, prednisolone phosphate, hydrocortisone phosphate, prednisolone succinate, and hydrocortisone succinate.
Examples of non-steroidal anti-inflammatory agents include loxoprofen sodium, and diclofenac sodium. Examples of prostanoids include Prostaglandin Ei (PGEx) , while examples of antimicrobial agents include vancomycin, chloramphenicol succinate, latamoxef, cefpirome, clindamycin phosphate, and carumonam. Examples of anticancer agents include, but are not limited to, vincristin, and vinblastine. In one exemplary process of the present invention, the intravenous nanoparticles are produced in the following manner: The low-molecular weight, water-soluble and non-peptide drug is first bound to the metal ion to make the agent hydrophobic. The drug is then dissolved or suspended, along with PLGA or PLA, in a water- miscible organic solvent. The resulting solution or suspension is added to an aqueous solution of a surfactant and the mixture is stirred to obtain the desired nanoparticles.
Examples of the water-miscible organic solvents for use in the present invention include, but are not limited to, acetone, acetonitrile, ethanol, methanol, propanol, dimethylformamide, dimethylsulfoxide, dioxane, and mixtures thereof.
Examples of the surfactants include polyoxyethylene polyoxypropylene glycols, polysorbates, polyoxyethylene octylphenyl ethers, lecithin, and polyvinylalcohol.
Preferably, the nanoparticles of the present invention so produced are purified by centrifugation, gel filtration, fiber dialysis, or ultrafiltration and are subsequently freeze-dried for storage to ensure the stability of PLGA or PLA as ingredient.
Upon freeze-drying, a stabilizing agent and an isotonizing agent are preferably added to the nanoparticles suspension so that the freeze-dried preparation can be resuspended for administration. Preferred examples of the stabilizing agent and isotonizing agent include sucrose and trehalose, which are preferably added in an amount (by weight) 5 times or greater than the amount of the nanoparticles .
The nanoparticles prepared in the above-described manner are intravenously administered to target various inflammatory sites, vascular lesions, infected sites, and malignant tumor tissues where the particles effectively accumulate and sustainedly release the encapsulated low-molecular weight, water-soluble and non-peptide drug over time to provide the desired biological activities for a prolonged period of time. This is where another advantageous feature of the nanoparticles of the present invention comes in: the metal ion acts to prevent the encapsulated low-molecular weight, water- soluble and non-peptide drug from bursting release out of the nanoparticles at an early stage after administration, thereby allowing the sustained release of the drug for a prolonged period of time.
Thus, in order for the nanoparticles to be usable as a medical formulation, it is important to control, depending on the intended purposes, the surface properties and the particle size of the nanoparticles, as well as the encapsulation rate and the release profile of the • low-molecular weight, water-soluble and non-peptide drug. For instance, the surface properties of the nanoparticles can be controlled by using different types of surfactants.
Adjusting the particle size of the nanoparticles is important also because the distribution of the nanoparticles within living body is strongly influenced by the particle size. To this end, the size of the nanoparticles is adjusted by taking into account how well the particles accumulate to different lesion sites (e.g., inflammatory sites, vascular lesion sites, infected sites, and malignant tumor tissues) . Specifically, the particle size can be adjusted by controlling the conditions during the preparation of the nanoparticles, including the rate at which the aqueous phase is stirred, the amount of the organic solvent used, and the rate at which the organic solvent is added to aqueous phase.
The efficiency of encapsulation of the low-molecular weight, water-soluble and non-peptide drug into the PLGA or PLA nanoparticles largely depends on the physical properties of the low- molecular weight drug. In general, hydrophilic (water-soluble) drugs tend to be incorporated into the PLGA or PLA nanoparticles less efficiently than hydrophobic drugs. For this reason, the low- molecular weight, water-soluble and non-peptide drug for use in the present invention needs to be bound to a metal ion to impart a hydrophobicity to the agent. Specifically, this is done by allowing the low-molecular weight, water-soluble and non-peptide drug to bind to a metal ion in such a manner that the drug forms water-insoluble precipitates .
For that purpose, such functional groups as phosphate and carboxyl, which are capable of binding to the metal ion, are preferably introduced into the molecules of the low-molecular weight, water-soluble and non-peptide drug. It is also required that any functional groups present in the drug molecules that do not participate in, or interrupt, the formation of the precipitation with the metal ion must be protected with proper protective groups. Furthermore, the type and amount of the organic solvent used and the rate at which the organic solvent is poured also affect the particle size of the nanoparticles and therefore need to be optimized. With respect to the PLGA and PLA that serve as ingredient of the nanoparticles, PLGA or PLA with different molecular weights may be used to adjust the rate at which the encapsulated low-molecular weight, water-soluble and non-peptide drug is released from the nanoparticles .
To evaluate the nanoparticles of the present invention, it is essential to construct in vitro or animal {in vivo) models suitable' for the evaluation of PK/PD (pharmacokinetics/pharmacodynamics) of the nanoparticles. As described above, the present invention has achieved a high encapsulation rate of the low-molecular weight, water-soluble and non-peptide drug into the PLGA or PLA nanoparticles by the use of metal ions to impart a hydrophobicity to the drug. The present invention allows the simple, industrial-scale production of the intravenous nanoparticles designed for the purpose of targeting drug delivery to target lesion sites where the particles can gradually release the drug over a prolonged period of time.
EXAMPLES The present invention will now be described in detail with reference to examples and test examples .
Example 1: Formation of water-insoluble precipitates of low- molecular weight, water-soluble and non-peptide drug with metal ion Compounds shown in Table 1 below were used to as the low- molecular weight, water-soluble and non-peptide drug having phosphate groups. Each compound was dissolved in a 0.2M Tris-HCl •buffer solution (pH7.8) to a concentration of 20mM. The solution was then added to equal volume of lOOmM aqueous solutions of different metal ions. The turbidity of each of the resulting mixtures was observed.
The results are shown in Table 1 below.
Figure imgf000012_0001
The resulting mixture was evaluated as follows: -: the compound was dissolved; +: the mixture was slightly turbid;
++: the mixture was significantly turbid; +++: the mixture was significantly turbid and a precipitation was formed.
As can be seen from the results of Table 1, a significant turbidity and precipitate formation were observed in each of the phosphate-containing compounds in the presence of zinc, iron (ferric or ferrous) , or copper ion.
When the molar ratio of the betamethasone phosphate to zinc ion and the molar ratio of riboflavin phosphate to zinc ion were varied to examine the amounts of the resulting precipitates, the precipitate formation was most significant for each of the low- molecular weight compounds when the molar ratio with respect to zinc ion was approximately 1.
Example 2 : Preparation of PLGA/PLA nanoparticles encapsulating steroids
Different steroids were dissolved in lOOμl water and the resulting solutions were each added to 500μl of a 0.5M aqueous zinc acetate solution or 500μl of a 0.5M aqueous ferrous chloride solution. Each mixture was centrifuged at 12,000rpm for 5min and the supernatant was discarded to obtain precipitates in the form of zinc-steroids or iron-steroids. To the precipitates, 500μl of acetone, an acetone/acetonitrile mixture, or an acetone/ethanol mixture dissolved 20mg PLGA or PLA (WAKO PURE CHEMICAL INDUSTRIES LTD. ) were added respectively. To each of the resultant solutions, an aqueous solution of zinc acetate was added and the mixture was allowed to stand for 2 hours at room temperature. Subsequently, the solution (or suspension) was added at the rate of lml/min via a 27G syringe to a 0.5% aqueous solution of Pluronic F68 (a nonionic high- molecular weight surfactant) stirring at 400rpm, to give nanoparticles. The resultant nanoparticles were stirred for 1 to 2 hours at room temperature, and a 0.5M aqueous solution of EDTA (pH8) was added (0.4 by volume) . The mixture was then centrifuged at 20,000G for 20min. Following the removal of the supernatant, the residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles. The resulting nanoparticles were added to a 2N aqueous solution of NaOH to decompose PLGA/PLA, and the steroid content in the nanoparticles was determined by HPLC. Similarly, the amount of water-insoluble steroid was determined for the nanoparticles prepared by different method without metal ions . Furthermore, precipitates formed by mixing 5mg betamethasone phosphate with zinc were dissolved in varying volume of acetone and then encapsulation efficiency of betamethasone phosphate incorporated in the nanoparticles was determined in the same manner as described above.
The results are shown in Tables 2 and 3 below. Table 2: Encapsulation of steroids into PLGA nanoparticles
BDP: betamethasone dipropionate BP: betamethasone phosphate DP: dexamethasone phosphate HP: hydrocortisone phosphate
Figure imgf000014_0002
* Data not obtained because of particle aggregation
As shown in Table 2, the use of the precipitates of the steroid phosphates that were generated through the addition of zinc or ferrous ion (i.e., BP-Zn, BP-Fe, DP-Zn, and HP-Zn) significantly increased the encapsulation rate of the respective steroids into PLGA nanoparticles, as opposed to the cases of the steroid phosphates provided in the form of sodium salts, each of which showed substantially no incorporation into the nanoparticles.
Table 3 shows the encapsulation rates of betamethasone phosphate into PLGA nanoparticles obtained by varying the amount of the solvent, acetone, while maintaining the amounts of PLGA and betamethasone phosphate. As can be seen from these results, the nanoparticles formed aggregates in 500μl or less of acetone. The particles on the other hand remained stably dispersed in 700μl acetone while showing a high encapsulation rate of betamethasone phosphate into the nanoparticles. Although the nanoparticles were stably dispersed in 700μl or more acetone, the encapsulation rates gradually decreased as the amount of acetone was increased.
Example 3: Steroid release profile from PLGA/PLA nanoparticles
5mg betamethasone phosphate was dissolved in lOOμl water and the solution was added to 500μl of a 0.5M aqueous solution of zinc acetate. The mixture was then centrifuged at 12,000rpm for 5min and the supernatant was discarded to obtain a zinc-steroid precipitate. To the precipitate, 500μl of acetone dissolved 20mg of PLGAs or PLAs with different molecular weights was added. The solution was allowed to stand for 2 hours at room temperature and was subsequently added, at a rate of lml/min with a 27G syringe, to a 0.5% suspension of either Pluronic F68 (a nonionic high-molecular weight surfactant) or lecithin that had been stirred at 400rpm. The resulting nanoparticles were stirred for 1 to 2 hours at room temperature. Following the addition of EDTA, the nanoparticles were subjected to ultrafiltration on Centriprep YM-10 (Amicon) for concentration and washing. The nanoparticles were then suspended in a mixture of FBS (fetal bovine serum) /PBS (v/v=l) at a 500μg/mL PLGA concentration and, after a predetermined period of time, a 0.5M aqueous solution of EDTA (pH8) was added (0.4 by volume) . The suspension was then centrifuged at 20,000G for 30min and the supernatant was discarded. The residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles . The resulting nanoparticles were added to a 2N aqueous solution of NaOH to hydrolyze PLGA/PLA, and the steroid content in the nanoparticles was determined by HPLC. As a control, nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, were prepared according to a method proposed by the present inventors in a previous patent application (Japanese Patent Application No. 2002-159190) . The amount of the encapsulated steroid was determined in the same manner. The results are shown in Table 4 below. Table 4 : Release of betamethasone from nanoparticles
Figure imgf000016_0001
*1: Nanoparticles prepared according to the method described in Japanese
Patent Application No. 2002-159190 *2: Nanoparticles prepared according to the method of the present invention
It was demonstrated that the nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, and prepared according to the method previously proposed by the present inventors (Japanese Patent Application No. 2002-159190) released a significant amounts of betamethasone at an early stage with approximately 90% or more of betamethasone having been released after 6 days. In contrast, the nanoparticles prepared according to the method of the present invention, in which the steroid's initial bursting release is significantly reduced, released the steroid in a more gradual manner and were able to release it over an extended period of time.
It has also been demonstrated that the nanoparticles made of PLGA or PLA with small molecular weights tend to release the steroid at an earlier stage and that the nanoparticles made of PLGA tend to release the steroid earlier than those made of PLA.
Example 4: Release profile of steroids from nanoparticles internalized by macrophages
Macrophages were collected from the abdominal cavities of mice that had been stimulated by intraperitoneal administration of 1.5ml of 10% proteose peptone. The cells were inoculated at 6 x 105 cells/12 wells and were cultured overnight in Macrophage-SFM medium (Gibco) . Subsequently, the culture medium was replaced, and the PLGA or PLA nanoparticles prepared according to the procedures described in Example 3 were added. The cells were incubated at 37 °C for another 2 hours . Subsequently, the cells were washed 8 times with PBS and the medium, and the amount of betamethasone in the medium was determined at pre-determined intervals by ELISA method.
As a control, nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, were prepared according to a method previously proposed by the present inventors (Japanese Patent Application No. 2002-159190) and were also added to the cells.
The results are shown in Table 5 below.
Table 5 : Release profiles of betamethasone from macrophages internalizing nanoparticles
Figure imgf000017_0001
*1: Nanoparticles prepared using PLA (MW 14,000) (Japanese Patent
Application No. 2002-159190) *2 : Nanoparticles prepared using PLGA (MW 8,000)
It was demonstrated that the nanoparticles encapsulating BDP (betamethasone dipropionate) , a hydrophobic steroid, and prepared according to the method previously proposed by the present inventors (Japanese Patent Application No. 2002-159190) had released most of betamethasone as early as after 2 days. In contrast, the nanoparticles prepared according to the method of the present invention showed a nearly linear release profile during the first 2 to 3-day period and continued to gradually release betamethasone for a succeeding period. Example 5 : Evaluation of dispersion stability of the nanoparticles
The acetone solutions prepared according to the procedures described in Example 3 were added dropwise to aqueous solutions of different surfactants to obtain nanoparticles . The resulting nanoparticles were concentrated, washed, purified, and were then freeze-dried in sucrose solutions of varying concentrations . The freeze-dried nanoparticles were resuspended in water and particle sizes of the particles were measured using a light-scattering photometer. All of the nanoparticles prepared by using aqueous solutions of different surfactants, namely, lecithin, polyoxyethylene polyoxypropylene glycols, and polysorbates, had substantially the same particle size. No significant differences were observed among the surfactants in the size and the dispersion stability of the nanoparticles, and in the encapsulation rate of betamethasone phosphate even when the concentrations of the surfactants were varied in the range from 0.01 to 1%.
In comparison, the nanoparticles prepared with a polyvinylalcohol solution were larger in size than those prepared with other surfactants and had a low encapsulation rate of betamethasone phosphate. It was also shown that the re- dispersibility of the freeze-dried nanoparticles by adding sucrose in an amount (by weight) more than 5 times the amount of the nanoparticles prior to freeze-drying the nanoparticles .
Example 6: Accumulation of nanoparticles in inflammatory sites
Inflammation was induced by injecting lOOμl physiological saline containing 1% carrageenin in the left hind paw of male Lewis rats. After 4 hours, single dosages of rhodamine-encapsulating nanoparticles of two different sizes (200nm and 500nm) were injected into a tail vein. 2 hours after administration, the resultant leg edema was cut and cryostat sections were prepared. The tissue samples were observed with fluorescence microscopy. As controls, one group was administered with physiological saline and another group with rhodamine alone.
The intensity of fluorescence observed in tissue sections was significantly higher in the group given the 200nm nanoparticles than in the control group given physiological saline alone, indicating significant accumulation of the nanoparticles in the inflammatory sites.
No significant accumulation of the nanoparticles was observed in the group given rhodamine alone or the group administered with the 500nm nanoparticles.
Example 7: Activity to suppress adjuvant-induced arthritis
Arthritis was induced in 7-week old Lewis rats, weighing 130 to 160g and preconditioned for one week, by injecting, under ether anesthesia, 50μl of incomplete Freund's adjuvant solution (DIFCO) containing 6mg/mL M. Butyricum Desiccated (DIFCO) into the left hind paw. The animals were divided into groups so that there are no significant differences between the groups in terms of the volume of the left hind leg of the animals. 14 days after administration of M. Butyricum, a single dose of PLA nanoparticles encapsulating betamethasone phosphate was administered intravenously to one group.
As controls, single doses of betamethasone phosphate and phosphate-buffered saline (PBS) were subcutaneously administered to respective groups of rats and a single dose of limethason (MITSUBISHI PHARMA) was intravenously administered to another group. The ability of the nanoparticles to suppress inflammation was analyzed by measuring the volume of the left hind legs before and 7 days after the administration of the drug using water displacement technique . The results are shown in Table 6 below. Table 6: Abilities of the nanoparticles to suppress adjuvant-induced arthritis
Figure imgf000020_0001
*1: Betamethasone phosphate-encapsulating nanoparticles were prepared using PLA (MW 14000) . Nanoparticles were given in an amount corresponding to lOOμg Betamethasone phosphate.
*2: Given in an amount corresponding to lOOμg dexamethasone phosphate.
*3: Inflammation rate was calculated by the following equation:
Inflammation rate (%) = (measured leg volume - leg volume of normal rat un-injected adjuvant) / (leg volume before steroid administration - leg volume of normal rat un-injected adjuvant) x 100
As shown in Table 6, an anti-inflammatory effect comparable to that observed with the use of three times as much of the betamethasone phosphate was seen in the group administered with limethason, an anti-inflammatory agent already in clinical use, as early as 1 day after administration. As with the case where betamethasone phosphate alone was administered, the anti- inflammatory effect of limethason was gradually lost over time. In comparison, the PLA nanoparticles of the present invention encapsulating betamethasone phosphate exhibited, as early as 1 day after administration, a high anti-inflammatory effect comparable to that observed with limethason and continued to exhibit a strong effect over a succeeding 7-day period.
Example 8: Preparation of PLGA/PLA nanoparticles encapsulating PGEj lmg of PGEi was dissolved in 20μl ethanol and the solution was added to an 80μl 0.5M aqueous solution of ferrous (or ferric) chloride. The mixture was then centrifuged at 12,000rpm for 5min and the supernatant was removed to obtain an iron-PGEi precipitate. To this precipitate, PLGA (WAKO PURE CHEMICAL INDUSTRIES, LTD.) or PLA (WAKO PURE CHEMICAL INDUSTRIES, LTD.) in acetone was added. An aqueous solution of zinc acetate was further added and the solution was allowed to stand for 2 hours at room temperature. Using a 27G syringe, the solution (or suspension) was subsequently added, at a rate of lml/min, to a 0.5% suspension of either Pluronic F68 (a nonionic high-molecular weight surfactant) or lecithin that had been pre-stirred at 400rpm. The resulting nanoparticles were stirred for 1 to 2 hours at room temperature and a 0.5M aqueous solution of EDTA (pH8) was added (0.4 by volume). The suspension was then centrifuged at 20,OOOG for 20min and the supernatant was discarded. The residue was resuspended in water and the suspension was again centrifuged to wash the nanoparticles. The resulting nanoparticles were dissolved in acetonitrile, followed by dilution with PBS. The amount of PGEi was then determined by ELISA method.
As described in Example 4, macrophages were allowed to uptake the PGEi-encapsulating PLGA nanoparticles and the amount of PGEi contained in the medium was determined at intervals by ELISA. The results are shown in Table 7 below.
Table 7 : Release profile of PGEi from macrophages internalizing nanoparticles
Figure imgf000021_0001
*1: Nanoparticles prepared using PLGA (MW 8,000)
The encapsulation rate of PGEX into the PLGA nanoparticles was approximately 0.1 to 1% by weight . As can also be seen from the results shown in Table 7, PGEi was continuously released from the nanoparticles for 8 days although the release profile was not as good as that for betamethasone phosphate, a steroidal anti- inflammatory agent.
INDUSTRIAL APPLICABILITY
As set forth, the present invention provides intravenous PLGA or PLA nanoparticles that can encapsulate sufficient amounts of low- molecular weight, water-soluble and non-peptide drugs are less likely to burst at an early stage of administration, and are capable of releasing the drug for a prolonged period of time.
The intravenous nanoparticles of the present invention can be used to target various inflammatory sites, vascular lesion sites, infectious sites, and malignant tumor tissues and effectively accumulate in such sites or tissues where the encapsulated low- molecular weight, water-soluble and non-peptide drugs are released over time to exhibit their biological activities for a prolonged period of time. The potential medical impact that the nanoparticles of the present invention can bring about is thus significant.

Claims

1. Intravenous nanoparticles for targeting drug delivery and sustained drug release, characterized in that a low-molecular weight, water-soluble and non-peptide drug is made hydrophobic by metal ion and is encapsulated in nanoparticles formed with poly (lactic-co-glycolic acid) or poly (lactic acid), and a surfactant is applied to the surface of the nanoparticles of poly (lactic-co- glycolic acid) or poly (lactic acid) .
2. The intravenous nanoparticles according to claim 1, wherein the particles have a diameter of 50 to 300nm.
3. The intravenous nanoparticles according to claim 1, wherein the low-molecular weight, water-soluble and non-peptide drug has a molecular weight of 1000 or lower.
4. The intravenous nanoparticles according to claim 1, wherein the metal ion is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
5. The intravenous nanoparticles according to claim 1, wherein the low-molecular weight, water-soluble and non-peptide drug has a phosphate group to make the drug susceptible to hydrophobicization by the metal ion.
6. The intravenous nanoparticles according to claim 1, wherein the low-molecular weight, water-soluble and non-peptide drug has a carboxyl group to make the drug susceptible to hydrophobicization by the metal ion. 7. The intravenous nanoparticles according to claim 1, wherein the low-molecular weight, water-soluble and non-peptide drug is a steroidal anti-inflammatory drug, a non-steroidal anti- inflammatory drug, a prostanoid, an antimicrobial drug, or an anticancer drug. 8. The intravenous nanoparticles according to claim 1, wherein the surfactant is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, a lecithin, or a polyvinylalcohol .
9. A method for producing intravenous nanoparticles for targeting drug delivery and sustained drug release, comprising the steps of: hydrophobicizing a low-molecular weight, water-soluble and non-peptide drug by the use of metal ion; dissolving or suspending, along with a poly (lactic-co-glycolic acid) or a poly (lactic acid), the hydrophobicized drug in a water- miscible organic solvent; and adding the resulting solution or the suspension to an aqueous solution of a surfactant to apply the surfactant to the surface of the nanoparticles .
10. The method for producing intravenous nanoparticles according to claim 9, wherein the particles have a diameter of 50 to 300nm. 11. The method for producing intravenous nanoparticles according to claim 9, wherein the low-molecular weight, water- soluble and non-peptide drug has a molecular weight of 1000 or lower.
12. The method for producing intravenous nanoparticles according to claim 9, wherein the metal ion is any of zinc, iron, copper, nickel, beryllium, manganese, and cobalt.
13. The method for producing intravenous nanoparticles according to claim 9, wherein the low-molecular weight, water- soluble and non-peptide drug has a phosphate group to make the drug susceptible to hydrophobicization by the metal ion. -14. The method for producing intravenous nanoparticles according to claim 9, wherein the low-molecular weight, water- soluble and non-peptide drug has a carboxyl group to make the drug susceptible to hydrophobicization by the metal ion.
15. The method for producing intravenous nanoparticles according to claim 9, wherein the low-molecular weight, water- soluble and non-peptide drug is a steroidal anti-inflammatory drug, a non-steroidal anti-inflammatory drug, a prostanoid, an antimicrobial drug, or an anticancer drug.
16. The method for producing intravenous nanoparticles according to claim 9, wherein the surfactant is a polyoxyethylene polyoxypropylene glycol, a polysorbate, a polyoxyethylene octylphenyl ether, lecithin, or a polyvinylalcohol. 17. An anti-inflammatory/anti-rheumatoid drug containing nanoparticles encapsulating a water-soluble steroid according to claim 1, as an active ingredient.
18. The anti-inflammatory/anti-rheumatoid drug according to claim 17, wherein the water-soluble steroid is betamethasone phosphate.
PCT/JP2004/003246 2003-03-26 2004-03-11 Intravenous nanoparticles for targenting drug delivery and sustained drug release WO2004084871A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004224530A AU2004224530A1 (en) 2003-03-26 2004-03-11 Intravenous nanoparticles for targenting drug delivery and sustained drug release
CA002518223A CA2518223A1 (en) 2003-03-26 2004-03-11 Intravenous nanoparticles for targeting drug delivery and sustained drug release
JP2006507664A JP2006521367A (en) 2003-03-26 2004-03-11 Nanoparticles for intravenous injection for targeting and sustained release
US10/550,990 US20060233883A1 (en) 2003-03-26 2004-03-11 Intravenous nanoparticles for targeting drug delivery and sustained drug release
EP04719616A EP1594482A1 (en) 2003-03-26 2004-03-11 Intravenous nanoparticles for targeting drug delivery and sustained drug release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-084695 2003-03-26
JP2003084695 2003-03-26

Publications (1)

Publication Number Publication Date
WO2004084871A1 true WO2004084871A1 (en) 2004-10-07

Family

ID=33094996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/003246 WO2004084871A1 (en) 2003-03-26 2004-03-11 Intravenous nanoparticles for targenting drug delivery and sustained drug release

Country Status (8)

Country Link
US (1) US20060233883A1 (en)
EP (1) EP1594482A1 (en)
JP (1) JP2006521367A (en)
KR (1) KR20050115315A (en)
CN (1) CN100361651C (en)
AU (1) AU2004224530A1 (en)
CA (1) CA2518223A1 (en)
WO (1) WO2004084871A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007074604A1 (en) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. Nanoparticle containing water-soluble non-peptidic low molecular weight substance
WO2007083643A1 (en) * 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomaterial for osteogenesis containing osteogenesis promoter and nanogel
WO2007110152A2 (en) * 2006-03-24 2007-10-04 Lts Lohmann Therapie-Systeme Ag Polylactide nanoparticles
WO2008139804A1 (en) 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. Low-molecule drug-containing nanoparticle having sustained release negatively charged group
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2011049036A1 (en) * 2009-10-19 2011-04-28 株式会社Ｌｔｔバイオファーマ Low-molecular drug-containing nanoparticle
WO2012101639A2 (en) 2011-01-24 2012-08-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
EP2512459A2 (en) * 2009-12-15 2012-10-24 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2512487A2 (en) * 2009-12-15 2012-10-24 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
US8318208B1 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8518963B2 (en) 2009-12-15 2013-08-27 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9351933B2 (en) 2008-06-16 2016-05-31 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
US9895378B2 (en) 2014-03-14 2018-02-20 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
US10933129B2 (en) 2011-07-29 2021-03-02 Selecta Biosciences, Inc. Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1580216T3 (en) * 2002-10-31 2014-08-18 Nippon Kayaku Kk High molecular weight derivatives of camptothecins
RU2324701C2 (en) * 2003-03-20 2008-05-20 Ниппон Каяку Кабусики Кайся Micellar agent containing poorly water-soluble anticancer agent, anticancer drug and novel block copolymer
ES2410591T3 (en) 2004-09-22 2013-07-02 Nippon Kayaku Kabushiki Kaisha New block copolymer, micellar preparation and antineoplastic agent containing it as active ingredient
DE602006016103D1 (en) * 2005-05-11 2010-09-23 Nippon Kayaku Kk POLYMER DERIVATIVE OF CYTIDINE METABOLITE ANTAGONIST
KR20080106254A (en) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 Polymer conjugate of taxane
CA2652656A1 (en) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2658100A1 (en) * 2006-07-19 2008-01-24 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of combretastatins
JP5548364B2 (en) * 2006-10-03 2014-07-16 日本化薬株式会社 Polymer conjugates of resorcinol derivatives
US8617614B2 (en) 2006-10-19 2013-12-31 Ono Pharmaceutical Co., Ltd. Sustained release preparation for tissue regeneration therapy
WO2008056596A1 (en) * 2006-11-06 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
CN101808651B (en) 2007-09-28 2013-03-27 日本化药株式会社 Polymer conjugate of steroid
DK2214646T3 (en) * 2007-10-05 2021-10-04 Univ Wayne State DENDRIMERS FOR SUSTAINED RELEASE OF COMPOUNDS
WO2009139939A2 (en) * 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
WO2009116509A1 (en) * 2008-03-18 2009-09-24 日本化薬株式会社 Polymer conjugate of physiologically active substance
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
TWI467045B (en) 2008-05-23 2015-01-01 Sigma Aldrich Co High-k dielectric films and methods of producing high-k dielectric films using cerium-based precursors
US20100104652A1 (en) * 2008-10-27 2010-04-29 University Of Arkansas Use of advanced nanomaterials for increasing sepecific cell functions
JP5544357B2 (en) 2009-05-15 2014-07-09 日本化薬株式会社 Polymer conjugate of a physiologically active substance having a hydroxyl group
EP2611466B1 (en) 2010-08-30 2019-06-12 President and Fellows of Harvard College Shear controlled release of thrombolytic therapies for stenotic lesions
JP5856069B2 (en) 2010-11-17 2016-02-09 日本化薬株式会社 Polymer derivatives of novel cytidine antimetabolites
JP6049712B2 (en) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Metal bisphosphonate nanoparticles for anti-cancer treatment and imaging and bone disorder treatment
JP2013053103A (en) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd Liver-accumulative nanoparticle having drug encapsulated therein
AU2012305405B2 (en) 2011-09-11 2016-01-14 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US8974830B2 (en) * 2012-02-23 2015-03-10 Canon Kabushiki Kaisha Particles and contrast agent including the same for optical imaging
JP5966582B2 (en) * 2012-05-10 2016-08-10 日油株式会社 Cross-linked polymer, injectable hydrogel, hydrogel formation kit
CN105873569B (en) 2013-11-06 2020-07-28 芝加哥大学 Nanoscale carriers for delivery or co-delivery of chemotherapeutic agents, nucleic acids and photosensitizers
DE102014004512A1 (en) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Inorganic-organic hybrid compound
EP3193827A1 (en) * 2014-08-13 2017-07-26 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
MA42161A (en) 2014-10-14 2017-08-23 Univ Chicago NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THEM
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
JP7364552B2 (en) 2017-08-02 2023-10-18 ザ ユニバーシティ オブ シカゴ Nanoscale metal-organic layers and metal-organic nanoplates for X-ray-induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP2023542743A (en) 2020-09-29 2023-10-11 オックスフォード ユニヴァーシティ イノヴェーション リミテッド stroke treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
EP1002529A1 (en) * 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
WO2002096396A1 (en) * 2001-05-28 2002-12-05 Ltt Bio-Pharma Co., Ltd. Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938916A (en) * 1957-07-30 1960-05-31 Merck & Co Inc Zinc salts of steroid phosphates
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
DE69630514D1 (en) * 1995-01-05 2003-12-04 Univ Michigan SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002529A1 (en) * 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO2002096396A1 (en) * 2001-05-28 2002-12-05 Ltt Bio-Pharma Co., Ltd. Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALLEMANN, ERIC ET AL: "PEG-coated poly ( lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumors", JOURNAL OF PHARMACY AND PHARMACOLOGY (1995), 47(5), 382-7, 1995, XP009031737 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007074604A1 (en) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. Nanoparticle containing water-soluble non-peptidic low molecular weight substance
US8916206B2 (en) * 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
JP5131971B2 (en) * 2005-12-26 2013-01-30 株式会社Ｌｔｔバイオファーマ Water-soluble non-peptide low molecular weight drug-containing nanoparticles
WO2007083643A1 (en) * 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomaterial for osteogenesis containing osteogenesis promoter and nanogel
WO2007110152A2 (en) * 2006-03-24 2007-10-04 Lts Lohmann Therapie-Systeme Ag Polylactide nanoparticles
WO2007110152A3 (en) * 2006-03-24 2008-02-21 Lohmann Therapie Syst Lts Polylactide nanoparticles
US8003128B2 (en) 2006-03-24 2011-08-23 Lts Lohmann Therapie-Systeme Ag Polylactide nanoparticles
EP2156848A4 (en) * 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd Low-molecule drug-containing nanoparticle having sustained release negatively charged group
WO2008139804A1 (en) 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. Low-molecule drug-containing nanoparticle having sustained release negatively charged group
EP2156848A1 (en) * 2007-05-14 2010-02-24 LTT Bio-Pharma Co., Ltd. Low-molecule drug-containing nanoparticle having sustained release negatively charged group
KR101513318B1 (en) 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 Low-molecule drug-containing nanoparticle having sustained release negatively charged group
US9375481B2 (en) 2008-06-16 2016-06-28 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8609142B2 (en) 2008-06-16 2013-12-17 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8663700B2 (en) 2008-06-16 2014-03-04 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9579386B2 (en) 2008-06-16 2017-02-28 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9579284B2 (en) 2008-06-16 2017-02-28 Pfizer Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US8318208B1 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9393310B2 (en) 2008-06-16 2016-07-19 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8652528B2 (en) 2008-06-16 2014-02-18 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8623417B1 (en) 2008-06-16 2014-01-07 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US9351933B2 (en) 2008-06-16 2016-05-31 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8603534B2 (en) 2008-06-16 2013-12-10 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8617608B2 (en) 2008-06-16 2013-12-31 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8613954B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US8905997B2 (en) 2008-12-12 2014-12-09 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US9308179B2 (en) 2008-12-15 2016-04-12 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US9198874B2 (en) 2008-12-15 2015-12-01 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US9006254B2 (en) 2009-05-27 2015-04-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US9884112B2 (en) 2009-05-27 2018-02-06 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
WO2011049036A1 (en) * 2009-10-19 2011-04-28 株式会社Ｌｔｔバイオファーマ Low-molecular drug-containing nanoparticle
US9498443B2 (en) 2009-12-11 2016-11-22 Pfizer Inc. Stable formulations for lyophilizing therapeutic particles
US8637083B2 (en) 2009-12-11 2014-01-28 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US9872848B2 (en) 2009-12-11 2018-01-23 Pfizer Inc. Stable formulations for lyophilizing therapeutic particles
US8916203B2 (en) 2009-12-11 2014-12-23 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8603535B2 (en) 2009-12-11 2013-12-10 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8956657B2 (en) 2009-12-11 2015-02-17 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9835572B2 (en) 2009-12-15 2017-12-05 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US8518963B2 (en) 2009-12-15 2013-08-27 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2512459A4 (en) * 2009-12-15 2013-08-07 Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2512487A4 (en) * 2009-12-15 2013-08-07 Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
EP2512459A2 (en) * 2009-12-15 2012-10-24 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EP2512487A2 (en) * 2009-12-15 2012-10-24 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
US8912212B2 (en) 2009-12-15 2014-12-16 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9764031B2 (en) 2010-05-26 2017-09-19 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012101639A2 (en) 2011-01-24 2012-08-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles for dermal and systemic delivery of drugs
US10933129B2 (en) 2011-07-29 2021-03-02 Selecta Biosciences, Inc. Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
US9895378B2 (en) 2014-03-14 2018-02-20 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
US10071100B2 (en) 2014-03-14 2018-09-11 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

Also Published As

Publication number Publication date
AU2004224530A1 (en) 2004-10-07
JP2006521367A (en) 2006-09-21
CA2518223A1 (en) 2004-10-07
KR20050115315A (en) 2005-12-07
EP1594482A1 (en) 2005-11-16
CN1764442A (en) 2006-04-26
CN100361651C (en) 2008-01-16
US20060233883A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US20060233883A1 (en) Intravenous nanoparticles for targeting drug delivery and sustained drug release
Singh et al. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Wu et al. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer
Ferreira et al. Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Govender et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug
Xiao et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles
Dolatabadi et al. Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems
Menon et al. Polymeric nanoparticles for pulmonary protein and DNA delivery
Abtahi et al. Multifunctional stimuli-responsive niosomal nanoparticles for co-delivery and co-administration of gene and bioactive compound: In vitro and in vivo studies
Çırpanlı et al. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model
JP5484339B2 (en) Dendrimers for sustained release of composites
Li et al. A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease
Natesan et al. Chitosan stabilized camptothecin nanoemulsions: Development, evaluation and biodistribution in preclinical breast cancer animal mode
Moritz et al. Recent developments in the application of polymeric nanoparticles as drug carriers
Anwar et al. Biodegradable nanoparticles as drug delivery devices
Roberts et al. Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells
Thapa et al. Nanomedicine-based antimicrobial peptide delivery for bacterial infections: Recent advances and future prospects
Zha et al. Intranasal delivery of functionalized polymeric nanomaterials to the brain
CN108289833B (en) Stabilized assembled nanostructures for delivery of encapsulants
Wang et al. Magnolol-loaded core–shell hydrogel nanoparticles: drug release, intracellular uptake, and controlled cytotoxicity for the inhibition of migration of vascular smooth muscle cells
Montero et al. Biocompatibility studies of intravenously administered ionic-crosslinked chitosan-BSA nanoparticles as vehicles for antitumour drugs
Soumya et al. Recent advances on nanoparticle-based therapies for cardiovascular diseases
Bharadwaj et al. Formulation and biological stability of nanomedicines in cancer treatment
Tan et al. Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood–brain barrier
Deepak et al. c (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006507664

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004224530

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004719616

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004224530

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2518223

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20048078782

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006233883

Country of ref document: US

Ref document number: 10550990

Country of ref document: US

Ref document number: 1020057018102

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004719616

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057018102

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10550990

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004719616

Country of ref document: EP